Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WX390 + Toripalimab in STK11-mutant gastric-type endocervical adenocarcinoma
NCT06124963Phase 2Recruiting
- Sponsor
- Shanghai Jiatan Pharmatech
- Start
- Aug 2023
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of WXFL10030390 in gastric-type endocervical adenocarcinoma (GAS), sponsored by Shanghai Jiatan Pharmatech. Started Aug 2023; status: recruiting.
02
Drugs
WXFL10030390
03
Conditions
gastric-type endocervical adenocarcinoma (GAS)
Beyond the preview
Go deeper on NCT06124963.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06124963.